Paper9738873
Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease.
Martiniuk F and 10 others. Am J Med Genet, 1998. Cited by 154 papers, by iCite.
Cite this record
ConductScience Library. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Papers, record 9738873. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9738873
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glycogen Storage Disease Type II | Major topic |
| Heterozygote | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Infant | |
| Infant, Newborn | |
| Male | |
| Middle Aged | |
| New York |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MO1 RR00096 | NCRR NIH HHS | United States | M01RR000096 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02838368 | Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices | Background |
Source ClinicalTrials.gov
Cited by75
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 154 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41586257 | Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications. | Exp Biol Med (Maywood) | 2025 | https://conductscience.org/library/papers/41586257 | PubMed |
| 40969949 | Correction of Disease Phenotype in Pompe Disease Knockout Mice Following Cationic Lipid-GL-67-Mediated Gene Therapy. | DNA Cell Biol Rep | 2025 | https://conductscience.org/library/papers/40969949 | PubMed |
| 40524065 | Clinical and therapeutic clues from a long-term follow-up: a single center experience on a large LOPD population. | J Neurol | 2025 | https://conductscience.org/library/papers/40524065 | PubMed |
| 40502951 | Successful Pregnancy Outcome in Patient with Pompe Disease Despite Discontinuation of Enzyme Replacement Therapy. | Eur J Case Rep Intern Med | 2025 | https://conductscience.org/library/papers/40502951 | PubMed |
| 40329343 | Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/40329343 | PubMed |
| 40225932 | Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease. | Hum Mutat | 2024 | https://conductscience.org/library/papers/40225932 | PubMed |
| 39457174 | Effectiveness of Respiratory Muscle Training in Pompe Disease: A Systematic Review and Meta-Analysis. | Children (Basel) | 2024 | https://conductscience.org/library/papers/39457174 | PubMed |
| 39273088 | Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273088 | PubMed |
| 38361118 | Global carrier frequency and predicted genetic prevalence of patients with pathogenic sequence variants in autosomal recessive genetic neuromuscular diseases. | Sci Rep | 2024 | https://conductscience.org/library/papers/38361118 | PubMed |
| 38274468 | An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion. | Front Pediatr | 2023 | https://conductscience.org/library/papers/38274468 | PubMed |
| 37907381 | Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert Panel. | Mol Genet Metab | 2023 | https://conductscience.org/library/papers/37907381 | PubMed |
| 37759679 | A Comprehensive Update on Late-Onset Pompe Disease. | Biomolecules | 2023 | https://conductscience.org/library/papers/37759679 | PubMed |
| 36969713 | Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview. | Curr Treat Options Neurol | 2022 | https://conductscience.org/library/papers/36969713 | PubMed |
| 36245745 | Infantile-onset Pompe disease complicated by sickle cell anemia: Case report and management considerations. | Front Pediatr | 2022 | https://conductscience.org/library/papers/36245745 | PubMed |
| 35747179 | Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study. | EClinicalMedicine | 2022 | https://conductscience.org/library/papers/35747179 | PubMed |
| 35264382 | Non-specificity of symptoms in infantile-onset Pompe disease may delay the diagnosis and institution of treatment. | BMJ Case Rep | 2022 | https://conductscience.org/library/papers/35264382 | PubMed |
| 34501319 | Molecular Diagnosis of Pompe Disease in the Genomic Era: Correlation with Acid Alpha-Glucosidase Activity in Dried Blood Spots. | J Clin Med | 2021 | https://conductscience.org/library/papers/34501319 | PubMed |
| 34353347 | Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy. | Orphanet J Rare Dis | 2021 | https://conductscience.org/library/papers/34353347 | PubMed |
| 34020684 | Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants. | Orphanet J Rare Dis | 2021 | https://conductscience.org/library/papers/34020684 | PubMed |
| 33717985 | Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. | Mol Genet Metab Rep | 2021 | https://conductscience.org/library/papers/33717985 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9738873
GET https://conductscience.org/api/papers/v1/9738873/cited_by?page=2